Business · 17/09/2020Updated: 10/17/2026 · 1 min read
Eisai, Inc. Withdraws FDA Approval for Two New Drug Applications for BELVIQ
Summary
Eisai, Inc. has withdrawn the FDA's approval for BELVIQ (lorcaserin hydrochloride) and BELVIQ XR (lorcaserin hydrochloride) due to its own request, waiving the opportunity for a hearing.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →